Study points to potential new approach to treating neurodegenerative diseases like glaucoma and Alzheimer’s disease
Jul. 20, 2020—Researchers at Vanderbilt University Medical Center have shown for the first time that when one optic nerve in the eye is damaged, as in glaucoma, the opposite optic nerve comes to the rescue by sharing its metabolic energy.
Jul. 16, 2020—Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.
Jul. 25, 2019—The Vanderbilt Eye Institute (VEI) has received a $10 million gift that will fund regenerative visual neuroscience research to develop transformative therapies for eye diseases.
Nov. 29, 2018—Two Vanderbilt Eye Institute (VEI) researchers were recently awarded National Eye Institute (NEI) Audacious Goals Initiative (AGI) for Regenerative Medicine grants for $6.8 million over five years to develop new treatments for optic neuropathies and glaucoma, the leading cause of irreversible blindness.
Feb. 22, 2018—A team of researchers, led by David Calkins, PhD, vice chair and director of Research at the Vanderbilt Eye Institute, has made a breakthrough discovery in the field of glaucoma showing new hopes for treatments to preserve vision.
Oct. 2, 2014—Vanderbilt University has launched a regenerative visual neuroscience initiative to develop new ways of treating — and restoring sight to — people who have been blinded by glaucoma, macular degeneration, diabetic retinopathy and eye injuries.